Ken Griffin Fennec Pharmaceuticals Inc. Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$8.82 - $11.12 $429,657 - $541,699	48,714 New	48,714 $541,000
Q3 2023 Nov 14, 2023	SELL	$7.15 - $8.94 $183,154 - $229,007	-25,616 Reduced 65.14%	13,710 $102,000
Q2 2023 Aug 14, 2023	BUY	$7.27 - $9.82 $29,487 - $39,829	4,056 Added 11.5%	39,326 $347,000
Q1 2023 May 15, 2023	BUY	$7.38 - $10.35 $53,254 - $74,685	7,216 Added 25.72%	35,270 $293,000
Q4 2022 Feb 14, 2023	BUY	$7.63 - $10.22 $94,444 - $126,503	12,378 Added 78.96%	28,054 $269,000
Q3 2022 Nov 14, 2022	BUY	$5.71 - $8.54 $89,509 - $133,873	15,676 New	15,676 $127,000

14.9M

10K

83.8K

Ticker FENC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,067,300
Market Cap $104M
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.